<DOC>
	<DOCNO>NCT00095927</DOCNO>
	<brief_summary>This research study study drug call Amifostine treatment squamous cell carcinoma head and/or neck area .</brief_summary>
	<brief_title>Randomized Amifostine For SCCHN</brief_title>
	<detailed_description>Amifostine drug use treat moderate severe xerostomia ( dry mouth ) receive radiation therapy head neck cancer . It approve FDA use intravenously . This study plan examine effect xerostomia Amifostine use subcutaneously ( injection ) . Amifostine see effective use combat effect dry mouth , also side effect list later consent form . The purpose study examine effectiveness twice day radiation therapy give chemotherapy consist carboplatin paclitaxel ( Taxo 1 ) . This study examine effectiveness add Amifostine hop reduce side effect radiation .</detailed_description>
	<mesh_term>Head Neck Neoplasms</mesh_term>
	<mesh_term>Mucositis</mesh_term>
	<mesh_term>Xerostomia</mesh_term>
	<mesh_term>Radiation Injuries</mesh_term>
	<mesh_term>Paclitaxel</mesh_term>
	<mesh_term>Albumin-Bound Paclitaxel</mesh_term>
	<mesh_term>Carboplatin</mesh_term>
	<mesh_term>Amifostine</mesh_term>
	<criteria>Inclusion Criteria Histologically cytologically proven squamous cell carcinoma head neck . Biopsy prefer unless medically contraindicate . Primary tumor site eligible : oral cavity , oropharynx , hypopharynx larynx . Tumors nasal paranasal cavity also include . Unknown primary SCC neck also eligible . Stage 2 , 3 4 disease without evidence distant metastasis verify chest XRay , abdominal ultrasound CT ( case liver function test abnormality ) ; bone scan case local symptom . At least one uni bidimensionally measurable lesion start therapy ( induction therapy ag well chemoradiation ) . No previous head neck radiotherapy previous curative surgery SCCHN ( biopsy ) allow time study entry . Age ≥ 18 year . WHO performance status 0 1 ( section 13 , Appendix I ) No active alcohol addiction ( assessed medical caregiver ) . Life expectancy ≥ 12 week . Signed informed consent prior begin protocol specific procedure . Adequate bone marrow , hepatic renal function evidence follow : Hematology : neutrophil count ≥ 2.0 x 10 9/1 . platelet count ≥ 100 x 10 9/1 . hemoglobin ≥ 10 g/dl . Hepatic function : total bilinthin WNL . ASAT ( SGOT ) ALAT ( SGPT ) ≤ 2.5 x 1JLN . alkaline phosphatase ≤ 5 x ULN . patient ASAT ALAT &gt; 1.5 x ULN associate alkaline phosphatase &gt; 2.5 x ULN eligible study . Renal function : creatinine clearance ≥ 60 ml/min ( actual calculate CockcroftGault method follow : Weight ( kg ) x ( 140 — age ) /K x serum creatinine serum creatinine mg/dL K : 72 man K : 85 woman serum creatinine µmon/L K : 0.814 man K : 0.96 woman Patients must available treatment followup . Patients register trial must treat follow participate center Previous chemotherapy permit , provide induction form start radiation therapy use treat head neck cancer . Pregnant lactate woman , woman childbearing potential use adequate contraception . Previous current malignancy site , exception adequately treat situ carcinoma cervix uterus , basal squamous cell carcinoma skin cancer curatively treat surgery evidence disease least 3 year . Symptomatic peripheral neuropathy ≥ grade 2 NCICCTG criterion . Other serious illness medical condition include limited : Unstable cardiac disease despite treatment , myocardial infarction within 6 month prior study entry History significant neurologic psychiatric disorder include dementia seizure . Active uncontrolled infection . Active peptic ulcer . Hypercalcemia . Chronic obstructive pulmonary disease require hospitalization year precede study entry . Patients require intravenous alimentation . Patients experience weight loss 20 % body weight 3 month precede study entry ( unless purposeful ) Concurrent treatment anticancer therapy . Participation investigational trial within 30 day study entry . Previous treatment biologic therapy permit .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2017</verification_date>
	<keyword>radiation toxicity</keyword>
	<keyword>chemotherapeutic agent toxicity</keyword>
	<keyword>mucositis</keyword>
	<keyword>xerostomia</keyword>
	<keyword>stage II squamous cell carcinoma lip oral cavity</keyword>
	<keyword>stage III squamous cell carcinoma lip oral cavity</keyword>
	<keyword>stage IV squamous cell carcinoma lip oral cavity</keyword>
	<keyword>stage II squamous cell carcinoma oropharynx</keyword>
	<keyword>stage III squamous cell carcinoma oropharynx</keyword>
	<keyword>stage IV squamous cell carcinoma oropharynx</keyword>
	<keyword>stage II squamous cell carcinoma hypopharynx</keyword>
	<keyword>stage III squamous cell carcinoma hypopharynx</keyword>
	<keyword>stage IV squamous cell carcinoma hypopharynx</keyword>
	<keyword>stage II squamous cell carcinoma larynx</keyword>
	<keyword>stage III squamous cell carcinoma larynx</keyword>
	<keyword>stage IV squamous cell carcinoma larynx</keyword>
	<keyword>stage II squamous cell carcinoma paranasal sinus nasal cavity</keyword>
	<keyword>stage III squamous cell carcinoma paranasal sinus nasal cavity</keyword>
	<keyword>stage IV squamous cell carcinoma paranasal sinus nasal cavity</keyword>
	<keyword>untreated metastatic squamous neck cancer occult primary</keyword>
	<keyword>metastatic squamous neck cancer occult primary squamous cell carcinoma</keyword>
</DOC>